Pulmonary surfactant protein A (SP-A
Pulmonary surfactant is a mixture of lipids and proteins that functions to keep alveoli from collapsing at expiration (1) . Surfactant protein A (SP-A) 1 is the major protein constituent of the surfactant (2) . SP-A belongs to the collectin subgroup of the C-type lectin superfamily along with surfactant protein D (SP-D), mannose-binding protein (MBP), and conglutinin (3) . SP-A is now recognized as playing an important role in regulating innate immunity within the lung. This protein enhances the phagocytosis of Staphylococcus aureus (4), herpes simplex virus type I (5), type A Hemophilus influenzae (6) , Mycobacterium tuberculosis (7) , and Klebsiella (8) by alveolar macrophages. SP-A can bind with broad specificity to a variety of microorganisms including herpes simplex virus type I (9), Pneumocystis carinii (10) , and Aspergillus fumigatus (11) . The characteristics of transgenic mice with null alleles for SP-A (12) (13) (14) provide compelling in vivo evidence that SP-A is an important component of the innate immune system within the lung. Animals lacking SP-A exhibit reduced bacterial clearance and elevated pulmonary inflammation in response to microbial challenge.
Gram-positive bacteria including S. aureus cause infections that can be life-threatening. Peptidoglycan (PGN), a major cell wall component of Gram-positive bacteria, is a polymer of alternating N-acetylglucosaminyl and N-acetylmuramyl glycan whose residues are cross-linked by short peptides (15) . PGN, like lipopolysaccharides (LPS) from Gram-negative bacteria, can elicit the excessive release of proinflammatory cytokines from immune cells, which contribute to many of the adverse clinical manifestations of bacterial infections (16 -18) . CD14 and Toll-like receptors (TLRs) function as pattern-recognition receptors for these bacterial ligands (19, 20) . TLRs possess an intracellular domain homologous to that of interleukin-1 receptor (21) and participate in NF-B signaling cascades elicited by LPS and PGN. In vivo studies with mice harboring null alleles for TLR2 provide strong evidence that TLR2 is responsible for PGN-induced signaling (22, 23) . Recent in vitro studies with overexpression experiments also demonstrate that TLR2 confers cell responsiveness to PGN (24, 25) . Although CD14 alone appears incapable of signaling because it lacks a transmembrane domain, it is still capable of enhancing PGN-induced NF-B signaling mediated by TLR2 (24) .
SP-A binds rough serotypes but not smooth serotypes of LPS (26, 27) . The protein inhibits TNF-␣ secretion induced by smooth LPS (26, 28) but modestly enhances TNF-␣ release induced by rough LPS (26) in alveolar macrophages and U937 cells. We have shown that the direct interaction of SP-A with CD14 is the likely mechanism for modulating LPS-elicited cellular responses (26) . In addition to SP-A, the collectins, SP-D, and MBP also bind CD14 (29, 30) , suggesting this may be an important property of this protein family. The interaction of SP-D with CD14 may be also accompanied by modulation of the cellular response to ligands such as LPS. SP-A-deficient mice exhibit significant increases in the production of TNF-␣ and nitric oxide after intratracheal instillation of smooth LPS when compared with wild type mice (31) . Intratracheal administration of SP-A to SP-A-deficient mice diminished the production of the proinflammatory cytokines. Taken together with the in vitro observations of the inhibitory function of SP-A on smooth LPS-elicited TNF-␣ secretion (26, 28) , there is growing evidence that SP-A promotes an anti-inflammatory response to some bacterial ligands.
The role of SP-A in modulating innate immunity may be a key element to understanding the dual requirement of the lung to remain relatively quiescent in its inflammatory response to routine daily burdens of inspired LPS and easily dispatched microorganisms while remaining competent to mount a potent and vigorous response to specialized pulmonary pathogens. Many inhaled pathogens that reach the alveolus are thought to interact immediately with lung collectins because these proteins are highly enriched at this biological interface.
PGN elicits many of the clinical manifestations of Grampositive organisms, and we focused on the interactions of SP-A with PGN and the consequences of the interaction upon TNF-␣ secretion by alveolar macrophages and U937 cells. The specific objectives of this study were to determine 1) the interaction of SP-A with PGN, 2) the role of SP-A in modulating leukocyte cytokine responses to PGN, 3) the interaction between SP-A and TLR2, and 4) the role of SP-A in altering PGN interaction with TLR2. Our findings demonstrate that PGN is not a ligand for SP-A and that SP-A reduces the PGN-elicited proinflammatory cytokine release by reducing TLR2-PGN interactions.
EXPERIMENTAL PROCEDURES
Cells and Reagents-The macrophage-like cell line U937 (JCRB9021) was obtained from the Health Science Research Resources Bank (Osaka, Japan). L929 murine fibroblast cells were kindly provided by Dr. Kazuko Kajiyama (Chugai Pharmaceutical, Tokyo, Japan). The cells were maintained in endotoxin-free RPMI 1640 medium from Sigma with 10% heat-inactivated fetal calf serum (FCS; Invitrogen). Human embryonic kidney (HEK) 293 cells (CRL-1573) were obtained from American Type Culture Collection and grown in Dulbecco's modified Eagle's medium containing 10% FCS. PGN derived from S. aureus was purchased from Fluka. The PGN contained 66.84 Ϯ 2.48 pg (mean Ϯ S.E., n ϭ 3) of endotoxin/mg when measured by a Limulus amebocyte lysate assay system (ENDOSPECY; Seikagaku Kogyo, Tokyo, Japan). Smooth LPS (Escherichia coli O26:B6) and rough LPS (Salmonella minnesota Re595) were obtained from Sigma.
Isolation of Rat Alveolar Macrophages-Alveolar macrophages were isolated from bronchoalveolar lavage fluids of Sprague-Dawley rats. The lungs were lavaged with pyrogen-free saline (Otsuka Pharmaceutical Co., Tokyo Japan), and alveolar macrophages were sedimented by centrifugation at 150 ϫ g. Isolated macrophages were plated at 5 ϫ 10 5 cells/well in 24-well plates (Falcon) in RPMI 1640 medium containing 10% FCS. The cells were allowed to adhere for 2 h and then used for the experiments after washing with PBS to remove the unattached cells.
SP-A-Human surfactant was isolated from the bronchoalveolar lavage fluids of patients with alveolar proteinosis as described previously (32) . After delipidation of surfactant with 1-butanol (33), SP-A was purified by affinity chromatography on mannose-Sepharose 6B followed by gel filtration as described previously (34) . Rat SP-A was also purified from the lung lavage fluids of Sprague-Dawley rats that had been given intratracheal instillation of silica (35) by the method described above. Recombinant rat SP-A was expressed in Chinese hamster ovary K1 cells and purified as described previously (11) .
Removal of Endotoxin in SP-A Preparations-Endotoxin was removed from SP-A preparations using polymyxin B-agarose (Sigma) in the presence of octyl-␤-D-glucoside as described by McIntosh et al. (28) . The endotoxin-depleted human SP-A contained 0.159 Ϯ 0.023 pg (mean Ϯ S.E., n ϭ 5) of endotoxin/g of protein when measured by the Limulus amebocyte lysate assay system.
Binding of SP-A to PGN-Two methods were used to evaluate SP-A-PGN interactions. One method using microtiter wells was adapted from that described for LPS binding (26, 29) . Briefly, 5 g/well PGN, Re595 LPS, or O26:B6 LPS in 20 l of ethanol was added onto microtiter wells (Immulon 1B; Dynex Laboratories, Chantilly, VA), and the solvent was evaporated in ambient air. Nonspecific binding to the wells was blocked with PBS (pH 7.4) containing 0.1% (v/v) Triton X-100 and 3% (w/v) skim milk (buffer A). The indicated concentration of rat SP-A (50 l/well) in 20 mM Tris (pH 7.4) containing 0.15 M NaCl, 5 mM CaCl 2 , and 1 mg/ml BSA was then added and incubated for 3 h at 37°C. After the incubation, the wells were washed with buffer A and were then incubated with 10 g/ml anti-SP-A IgG (50 l/well) in buffer A for 1 h followed by the incubation with horseradish peroxidase-labeled antirabbit IgG (1:1000) for 1 h. The peroxidase reaction was finally performed using o-phenylenediamine as a substrate after washing the wells with PBS containing 0.1% (v/v) Triton X-100. The binding of SP-A to PGN or LPS was detected by measuring absorbance at 492 nm.
Because the PGN obtained was insoluble, we also carried out the binding study by sedimentation based on methods used for the binding of SP-A to phospholipid liposomes (36) . We first tested whether insoluble PGN was localized in the pellet after sedimentation. Ten micrograms of insoluble PGN was centrifuged at 10,000 ϫ g at room temperature for 10 min and separated into the supernatant and the pellet. The ability of each fraction to induce TNF-␣ secretion from U937 cells was examined by measuring secreted TNF-␣ using an L929 cell cytotoxicity assay. For the binding study, the rat SP-A preparation (200 ng/tube) in 50 l of 20 mM Tris buffer (pH 7.4) containing 0.1 M NaCl and 2% (w/v) BSA (buffer B) was centrifuged at 10,000 ϫ g at room temperature for 10 min. The PGN preparation was also centrifuged at the same time. The supernatant of the protein solution was added to the PGN pellet. The mixture of the protein and the PGN was suspended and incubated in the presence of 5 mM CaCl 2 or 5 mM EDTA for 1 h at 37°C. The mixture was then centrifuged at 10,000 ϫ g at room temperature for 10 min. The supernatant was stored, and the resultant pellet was resuspended in 50 l of buffer B and centrifuged again. The supernatants were then combined, and the pellet was suspended in 100 l of the buffer B. The amount of SP-A in each fraction was determined by sandwich enzyme-linked immunosorbent assay using anti-SP-A IgG.
Induction of TNF-␣ Secretion-U937 cells (5 ϫ 10 5 /well) were placed on 24-well plates (Falcon) and induced to differentiate by incubation with 10 nM PMA for 24 h. The cells were further incubated in the absence of PMA for 24 h in RPMI 1640 medium containing 10% FCS. Alveolar macrophages (5 ϫ 10 5 /well) were incubated on 24-well plates for 2 h after isolation from the bronchoalveolar lavage fluids of rats. The indicated concentration of SP-A was preincubated with the cells 30 min before adding PGN. The indicated amount of PGN was then added into the well and incubated for 5 h at 37°C with 5% CO 2 . The cultured medium was collected and assayed for TNF-␣ concentrations using the L929 cell cytotoxicity assay as described below.
Measurment of TNF-␣ Concentration-TNF-␣ secretion into medium from U937 cells or rat alveolar macrophages was measured using L929 cell cytotoxicity assay performed by a modified method (26) based on that described by Flick and Gifford (37) . Briefly, the L929 cells were seeded into 96-well plates (6 ϫ 10 4 /well) in 100 l/well RPMI 1640 containing 10% FCS and 2 g/ml actinomycin D (Sigma). Dilutions of standard recombinant TNF-␣ (1-50 pg/ml) (PeproTech, Rocky Hill, NJ) or samples (1:10 for U937 cells or 1:80 for rat alveolar macrophages) in a volume of 100 l/well were added, and the cells were incubated at room temperature for 15 min followed by incubation at 37°C overnight with 5% CO 2 . On the next day the medium was removed, and the cells were stained with 0.2% (w/v) crystal violet for 10 min. The wells were then washed with water, and 100 l/well 33% acetic acid was added to extract the retained crystal violet. The absorbance at 570 nm was finally measured.
NF-B Reporter Gene Assay-The 2.6-kilobase cDNA for human TLR2 was obtained by reverse transcription-polymerase chain reaction using RNA isolated from U937 cells. NF-B activation was measured as previously described (24, 38) . HEK293 cells were plated at 1 ϫ 10 5 /well on 24-well plates on the day before transfection. The cells were transiently transfected by FuGENE TM 6 transfection reagent (Roche Molecular Biochemicals) according to the manufacturer's instruction, with 0.02 g of TLR2 cDNA in pcDNA3.1(ϩ) plasmid vector (Invitrogen), 0.1 g of an NF-B reporter construct (pNF-B-Luc, Stratagene), and 0.01 g of a construct directing expression of Renilla luciferase (pRL-TK, Promega). Forty-eight hours after transfection, the cells were stimulated with 5 g/ml PGN for 6 h in the absence or the presence of SP-A (50 g/ml), which was preincubated with the cells for 2 h before adding PGN to the wells. Luciferase activity was measured using the dualluciferase reporter assay system (Promega) according to manufacturer's instruction.
Binding of SP-A to sTLR2-Expression and purification of a soluble form of recombinant extracellular domain of TLR2 (sTLR2) will be described elsewhere.
2 sTLR2 consists of the putative extracellular domain (Met 1 -Arg 587 ) of TLR2 and a 6-histidine tag at its C-terminal end and was expressed in baculovirus-insect cell expression system. The sTLR2 protein was isolated from the culture medium by an affinity column of nickel-nitrilotriacetic acid beads, as previously described for the isolation of sCD14 (29) .
The ligand blot analysis was performed by the method based on that described for the binding of SP-A to sCD14 (26) . Two micrograms of sTLR2 was electrophoresed on 13% polyacrylamide gel in the presence of SDS under denaturing conditions and transferred onto polyvinylidene difluoride membrane. The membrane was incubated with 5 mM Tris buffer (pH 7.4) containing 0.15 M NaCl, 5 mM CaCl 2 , 5% (w/v) BSA (buffer C) to block nonspecific binding. The membrane was then incubated with 5 g/ml human SP-A in buffer C at room temperature for 3 h. The membrane was washed and incubated with anti-SP-A IgG (10 g/ml) for 90 min followed by the incubation with horseradish peroxidase-labeled anti-rabbit IgG (1: 1500) for 60 min. The binding of human SP-A to sTLR2 was finally visualized by chemiluminescence (Super Signal, Pierce).
The binding of SP-A to sTLR2 was also examined using microtiter wells. sTLR2 or BSA (10 g/ml, 50 l/well) was coated onto microtiter wells. The wells were incubated with buffer A to block nonspecific binding. The indicated concentrations of human or rat SP-A in 10 mM HEPES (pH 7.4) containing 0.15 M NaCl, 5 mM CaCl 2 , and 1% (w/v) BSA was then incubated at 37°C for 6 h. Anti-SP-A polyclonal IgG (20 g/ml) was incubated at 37°C for 60 min after washing the wells with the buffer A followed by the incubation with horseradish peroxidaselabeled anti-rabbit IgG (1:1000) at 37°C for 60 min. The wells were washed with PBS (pH 7.4) containing 0.1% (v/v) Triton X-100. The binding of human or rat SP-A was finally detected by using o-phenylenediamine as a substrate for the peroxidase reaction, and the absorbance at 492 nm was measured. I-labeled proteins were solubilized in 200 l of 0.1 M NaOH, and the radioactivity was quantified using a ␥-radiation counter. In some experiments, 125 I-SP-A (5 g/ml) was preincubated with 50 g/ml anti-human SP-A monoclonal antibody PE10 or control monoclonal antibody 3C9 or mouse control IgG or 0.2 M carbohydrate in the buffer D at 37°C for 1 h. The mixture was then incubated with sTLR2 coated onto microtiter wells at 37°C for 6 h. The wells were then washed, and the amounts of the labeled protein binding to the wells were determined as described above. A binding reaction with heat-treated (100°C, 5 min) 125 I-SP-A was also performed. Five mM EDTA was also included in the binding buffer instead of 5 mM CaCl 2 to examine the effect of Ca 2ϩ on the SP-A binding to sTLR2. Effect of SP-A on the Binding of sTLR2 to PGN-sTLR2 was iodinated by the method of Bolton and Hunter (39) using the Bolton-Hunter reagent (Amersham Biosciences, Inc.) as described above for the iodination of SP-A. Ten g of PGN in 20 l of ethanol was added to the microtiter wells, which were subsequently dried in ambient air. The wells were incubated with buffer D to block nonspecific binding.
125
IsTLR2 protein (0.5-5 g/ml) was then incubated with PGN coated onto the microtiter wells at 37°C for 6 h. The wells were washed with PBS (pH 7.4) containing 0.1% (v/v) Triton X-100, and then the proteins were solubilized in 200 l of 0.1 M NaOH, and the bound radioactivity was quantified using a ␥-radiation counter. To examine the effect of SP-A on the binding reaction with PGN, human SP-A (5 or 100 g/ml) was preincubated with 125 I-sTLR2 (1 or 2 g/ml) at 37°C for 2 h before addition to the wells.
RESULTS

PGN Is Not a Ligand for SP-A-To examine the interaction
of SP-A with PGN, we first performed binding experiments using a solid phase assay. We have previously shown that SP-A bound to rough LPS (Re 595) with high affinity but not to smooth LPS (O26:B6) (26) . In the current study we used these two different strains of LPS as controls. SP-A avidly bound to Re595 LPS coated onto microtiter wells, but the protein exhibited almost no binding to O26:B6 LPS. When 0 -10 g/ml SP-A was incubated with the solid phase PGN, no significant binding was observed at any concentrations of the protein.
We next carried out the binding assay in solution by a sedimentation method. The localization of PGN was determined by examining the ability of the centrifuged fractions to induce TNF-␣ secretion from U937 cells. The pellet fraction contained more than 99% TNF-␣-inducing activity. Admixture of SP-A and PGN followed by centrifugation revealed that no significant levels of the protein were recoverable in the pellet fraction. The recovery of SP-A in the supernatant was independent of the presence of Ca 2ϩ , EDTA, or PGN in various combinations. These findings demonstrate that PGN from S. aureus is not a ligand for SP-A.
SP-A Attenuates the Leukocyte Response to PGN-Next we investigated whether SP-A alters cellular responses induced by PGN in the U937 human macrophage-like cell line. The cells (5 ϫ 10 5 cells/well) were first differentiated by treatment with PMA and subsequently incubated with PGN for 5 h in the presence or the absence of human SP-A. TNF-␣ secretion into medium was quantified using the L929 cell cytotoxicity assay. PGN stimulated TNF-␣ secretion in a concentration-dependent manner (Fig. 1) . When 25 g/ml polymyxin B sulfate was included in the medium in the presence of 10 g/ml PGN, the level of TNF-␣ secreted was almost equivalent to that observed without polymyxin B (8300 versus 8800 pg/ml, mean of two experiments), indicating that the observed response is not due to endotoxin contamination. Human SP-A alone also did not induce TNF-␣ secretion in the absence of PGN. Coincubation of SP-A with the cells and 1-10 g/ml PGN inhibited PGN-elicited TNF-␣ secretion from U937 cells (Fig. 1) . Ten g/ml recombinant rat SP-A also decreased the level of TNF-␣ secretion to 35.3% (mean of two experiments) of that stimulated by 1 g/ml PGN, indicating that the general effect is not speciesspecific, but the potency may vary with protein source.
Stimulation of U937 cells with 100 and 1000 nM PMA increased TNF-␣ secretion to 2807 Ϯ 861 and 6067 Ϯ 1146 pg/ml (n ϭ 3, mean Ϯ S.E.), respectively. When 20 g/ml human SP-A for 30 min at 37°C with 5% CO 2 . PGN (1-10 g/ml) was then added, and the cells were further incubated for 5 h. The culture medium was collected, and TNF-␣ secretion into the medium was determined by L929 bioassay as described under "Experimental Procedures." The data shown are mean ϩ S.E. of three experiments. *, p Ͻ 0.05, when compared with incubation without SP-A.
was coincubated with the cells in the presence of PMA, there was no attenuation of TNF-␣ secretion. The amounts of TNF-␣ secreted in the presence of SP-A were 2907 Ϯ 1033 and 7120 Ϯ 1028 pg/ml (n ϭ 3, mean Ϯ S.E.) for 100 and 1000 nM PMA, respectively. These results clearly indicate that the inhibitory effect of SP-A is not simply nonspecific for the activation of the cells used but specific for the PGN-induced cell responses.
To further confirm the inhibitory effect of SP-A on TNF-␣ production induced by PGN, we performed the experiments using rat alveolar macrophages. One to ten g/ml PGN was incubated with alveolar macrophages in the presence or the absence of 10 g/ml human SP-A (Fig. 2) . PGN induced very high levels of TNF-␣ release in a concentration-dependent manner in these macrophages. Up to 157.2 Ϯ 56.0 ng/ml (mean Ϯ S.E., n ϭ 3) TNF-␣ was secreted at 10 g/ml PGN. SP-A markedly reduced TNF-␣ secretion at all concentrations of PGN tested. Rat SP-A also decreased TNF-␣ secretion to 52.6% (mean of three experiments) of the level observed at 2 g/ml PGN in the absence of the protein. When various concentrations of human SP-A were incubated with alveolar macrophages stimulated with 5 g/ml PGN, the protein significantly reduced TNF-␣ secretion at all concentrations tested (Fig. 3) . Half-maximal inhibition was observed at ϳ20 g/ml of human SP-A.
SP-A Attenuates PGN-induced NF-B Activation in TLR2-transfected HEK293 Cells-Because recent in vivo and in vitro
studies (22) (23) (24) (25) demonstrate that PGN-induced signaling is mediated by TLR2, we examined the effect of SP-A on PGNinduced NF-B activation in TLR2-transfected HEK293 cells. PGN (5 g/ml) stimulated NF-B reporter activity in TLR2-transfected cells. SP-A treatment (50 g/ml) alone did not affect the basal NF-B activity (Fig. 4) . Coincubation of SP-A and PGN with the cells significantly attenuated the activity of measured NF-B. SP-A reduced the NF-B activity by ϳ34%. These data clearly indicate that SP-A can alter TLR2-mediated signaling.
SP-A Binds the Extracellular Domain of TLR2-We constructed a soluble form (sTLR2) of the extracellular TLR2 domain consisting of Met 1 -Arg 587 and a 6-histidine tag at its C-terminal end. sTLR2 was expressed using a baculovirusinsect cell expression system, and the protein was isolated by affinity chromatography. When sTLR2 was electrophoresed and transferred onto a polyvinylidene difluoride membrane, it was visualized as a band of ϳ75 kDa by Coomassie Blue staining (Fig. 5A) . For the ligand blot analysis, the membrane was incubated with human SP-A or BSA and probed with anti-SP-A IgG. SP-A that had bound to the membrane was detected as a band corresponding to that of sTLR2 (Fig. 5A ), demonstrating that SP-A binds to TLR2. We further examined the binding of SP-A to sTLR2 coated onto microtiter wells. SP-A bound to the solid phase sTLR2 but not BSA in a concentration-dependent manner (Fig. 5B) . From these results, we conclude that SP-A binds to the extracellular domain of TLR2.
To characterize the SP-A binding to sTLR2, 125 I-SP-A was also used for the microtiter well binding. Human SP-A exhibited concentration-dependent and saturable binding to solid phase sTLR2 (Fig. 6 ). An analysis of the binding as described by Klotz (40) (Fig. 6, inset) reveals that half-maximal binding occurs at 2.26 Ϯ 0.53 g/ml (n ϭ 3, mean Ϯ S.E.). When calculated as an oligomeric molecular mass (41), the binding of human SP-A to sTLR2 has a K 1/2 of 1.413 Ϯ 0.331 nM (n ϭ 3, mean Ϯ S.E.). Heat treatment (100°C, 5 min) of 125 I-labeled human SP-A and the inclusion of EDTA in the binding buffer almost completely abolished the binding of SP-A to sTLR2 (Fig.  7A) . However, coincubation of 125 I-labeled human SP-A with excess carbohydrates failed to reduce the SP-A binding to sTLR2. The effect of anti-SP-A monoclonal antibody was also examined (Fig. 7B) . The control antibodies (3C9 and mouse IgG) showed some nonspecific interference with the binding. Anti-human SP-A monoclonal antibody, PE10, almost completely blocked the SP-A binding to sTLR2. These results indicate that the binding of SP-A to sTLR2 is Ca 2ϩ -dependent. Because the epitope for PE10 localizes to a region contiguous with human SP-A Thr 184 -Gly 194 (42) , the data also strongly implicate the carbohydrate recognition domain of the protein in TLR2 recognition.
SP-A Decreases PGN-TLR2 Interactions-We next examined the interaction between sTLR2 and solid phase PGN. When 0.5-5 g/ml 125 I-sTLR2 was incubated with 10 g/well PGN coated onto microtiter wells, the protein exhibited concentrationdependent binding (Fig. 8A) . We next investigated the effect of human SP-A on the binding of sTLR2 to PGN. Human SP-A (0, 5, or 100 g/ml) was preincubated with 1 g/ml 125 I-sTLR2, and the mixture of SP-A and sTLR2 was further incubated with solid phase PGN. The amount of sTLR2 binding to PGN in the presence of SP-A was compared with that in the absence of SP-A. SP-A attenuated the binding of 125 I-sTLR2 to PGN in a concentration-dependent manner (Fig. 8B) . When 100 g/ml SP-A was incubated with 1 g/ml 125 I-sTLR2, the binding of the labeled sTLR2 to PGN was significantly decreased to the level of ϳ35% of that in the absence of SP-A. Increasing the 125 I-sTLR2 concentration to 2 g/ml reduced the SP-A inhibitory effect (32% inhibition at 100 g/ml). Initial experiments performed in this study focused on interactions between SP-A and PGN. Solid phase binding did not reveal any interaction between SP-A and PGN. However, we were not able to quantify the amount of PGN bound to the wells. We therefore conducted binding assays in solution with sedimentable PGN. Consistent with the solid phase binding results, SP-A failed to bind to PGN in solution. Taken together, we conclude that PGN derived from S. aureus is not a ligand for SP-A.
Previous studies from this (26) and other (28) laboratories demonstrate that SP-A inhibits smooth LPS-elicited TNF-␣ secretion by alveolar macrophages and U937 cells. SP-A has also been shown to down-regulate proinflammatory cytokine production elicited by Candida albicans (44) . In contrast to these studies, another study (45) reports that SP-A stimulates the production of cytokines including TNF-␣, interleukin-1, and interleukin-6. However, in vivo studies (31) using SP-A (Ϫ/Ϫ) mice give results consistent with an inhibitory role of SP-A on inflammatory cytokine production. SP-A (Ϫ/Ϫ) mice produced significantly increased TNF-␣ and nitric oxide in the lung compared with SP-A (ϩ/ϩ) mice after intratracheal administration of smooth LPS. Instillation of SP-A to SP-A (Ϫ/Ϫ) mice restored regulation of proinflammatory cytokine production. Another study (43) with SP-A (Ϫ/Ϫ) mice has shown that infection with group B streptococcus and H. influenzae increased the proinflammatory cytokines in the lung. In this report we sought to determine whether the antiinflammatory role for SP-A was also applicable to a PGN stimulus. This study demonstrates in vitro that SP-A attenuates TNF-␣ release induced by PGN derived from S. aureus. The SP-A effect on PGN responsiveness occurs with the U937 cell line as well as primary alveolar macrophages. The results obtained from this and the previous in vivo (31, 43) and in vitro (26, 28, 44) studies are consistent with the idea that SP-A plays a role in modulating cytokine production and inflammatory responses during bacterial infection within the lung.
We also sought to elucidate the mechanism by which SP-A inhibits PGN-elicited TNF-␣ secretion. Because this study has shown that SP-A does not bind to PGN, the mechanism of the inhibitory effect must be different from that by which MBP inhibits cellular responses caused by streptococcal cell wall components (46) . In the latter case, the direct interaction of MBP with streptococcal rhamnose glucose polymer (RGP) inhibits RGP-induced TNF-␣ secretion. A previous study (26) from this laboratory suggests that one of the possible mechanisms by which SP-A modulates LPS-induced cytokine expression is likely to be due to the interaction of SP-A with the LPS receptor, CD14. CD14 and TLR2 function as pattern recognition receptors for PGN (19, 20) . Because TLR2-deficient mice were hyporesponsive to PGN (22, 23) and transfection with a TLR2 cDNA conferred cell responsiveness to PGN on HEK293 cells (24) , TLR2 is concluded to be responsible for PGN-induced cellular responses. Although CD14 enhances PGN-induced cell signaling mediated through TLR2, TLR2 alone can induce significant NF-B activation in response to PGN. In addition, because PGN-or LPS-elicited TNF-␣ expression is coupled with TLR-mediated NF-B signaling, we examined the effect of SP-A on PGN-induced NF-B activation in TLR2-transfected HEK293 cells. SP-A significantly reduced the measured NF-B activity, indicating that SP-A can alter TLR2-mediated NF-B signaling.
Next, we constructed a soluble form of recombinant extracellular TLR2 domain (sTLR2) and isolated sTLR2 protein expressed by the baculovirus-insect cell expression system. The direct binding of PGN to the extracellular TLR2 domain has now been demonstrated. Additional details about this binding reaction will be described elsewhere. 2 The preincubation of SP-A with sTLR2 significantly reduced the binding of sTLR2 to PGN. These results obtained from the cell-free system are essentially consistent with those obtained using U937 cells and alveolar macrophages, although the magnitudes of the SP-A inhibition are different. The expression of TLR2 has been demonstrated in U937 cells (38) , leukocytes (47) , and lung (48) . Taken together, these data support the idea that the direct interaction of SP-A with the extracellular TLR2 domain interfere with PGN binding to TLR2, resulting in decreased TLR2-mediated NF-B signaling and reduced TNF-␣ secretion from immune cells. From the present and previous (26) studies we now propose that SP-A modulates cellular responses induced by bacterial ligands through direct interactions with pattern recognition receptors, CD14, and/or TLR. SP-A almost completely abrogated PGN-induced TNF-␣ secretion from U937 cells. However, this protein did not completely inhibit PGN-induced cytokine release in alveolar macrophages. The difference between SP-A's inhibitory effects on U937 cells and alveolar macrophages may be due to the different capacity of these cells to secrete TNF-␣. Ten g/ml PGN induced secretion of more than 150 ng/ml TNF-␣ in alveolar macrophages, whereas the same concentration of PGN applied to U937 cells produced 7.5 ng/ml TNF-␣. SP-A exhibited a greater inhibitory effect at lower concentrations of PGN than at higher concentrations in alveolar macrophages, with 80% inhibition at 1 g/ml versus 33% inhibition at 10 g/ml. SP-A did significantly attenuate, but did not completely abrogate, PGN-induced NF-B activation in TLR2-transfected cells or sTLR2 binding to solid phase PGN. The absence of a one to one correlation of the SP-A effect between TNF-␣ secretion and NF-B activity or sTLR2 binding to PGN may be a consequence of TLR2 overexpression or altered affinity for sTLR2. The naturally occurring soluble form of mouse TLR4, which is expressed by alternatively spliced mouse TLR4 mRNA, has been shown to only partially block LPS-elicited NF-B activation (49) , indicating that the extracellular domain alone may not explain all the activity of the receptor-ligand interaction. Clearly, more detailed biochemical data regarding SP-A-TLR2 and PGN-TLR2 interactions and the mechanism of signal transduction and the terminal inhibitory event are required.
We have previously shown that SP-A and SP-D bind CD14 by different mechanisms (29) . The SP-A neck domain and SP-D lectin domain participate in CD14 binding. SP-A and SP-D recognize a peptide portion and a carbohydrate moiety, respectively, of CD14. MBP also binds CD14 in a manner similar to that of SP-A (30). CD14 and TLRs possess homologous structures consisting of leucine-rich repeats characteristic of a short ␤-sheet and ␣-helix (50). CD14 and TLR2 contain 10 and 19 leucine-rich repeats, respectively. Because SP-A binds to the CD14 region containing leucine-rich repeats and also binds to deglycosylated sTLR2, 3 we infer that SP-A may interact with the leucine-rich repeat region of TLR2. The binding of rat SP-A to sCD14 was blocked by a monoclonal antibody that binds to the SP-A neck domain but was not attenuated in the presence of EDTA (29) , indicating that the SP-A neck domain participates in CD14 binding. In this study the binding of human SP-A to sTLR2 was abolished by a monoclonal antibody whose epitope is located at a region contiguous to the human SP-A region Thr 184 -Gly 194 (42) . In addition, it was blocked by the presence of EDTA, indicating that the SP-A binding to sTLR2 is Ca 2ϩ -dependent and that the carbohydrate recognition domain is involved in sTLR2 binding. These studies reveal the different mechanisms of the SP-A binding to the pattern recognition receptors. The molecular and mechanistic details by which SP-A and other collectins interact with TLRs are now under investigation.
It is relatively difficult to determine the actual SP-A concentration in vivo since the epithelial lining fluid of the alveolus (alveolar hypophase) cannot be directly measured. Nevertheless, the SP-A concentrations can be estimated based on the recovery of the protein in the bronchoalveolar lavage fluids and the extrapolated hypophase volume (100 -1000 l/lung) (51, 52) . The calculated SP-A concentrations in the alveolar hypophase range from 180 g/ml to 1.8 mg/ml (53) (54) (55) . The levels of SP-A appear to vary in diseased states, indicating complex responses under conditions of physiological stress. In the rat model, the levels of SP-A mRNA and protein are elevated in response to intratracheal administration of LPS (56) . SP-A recovered in the lavage fluid also increases in AIDS-related pneumonia (57) . However, in some situations (58) , the SP-A concentration in lavage fluid decreases in patients with bacterial pneumonia. Although one cannot yet determine the exact concentrations of SP-A in the hypophase of healthy and diseased human lungs, the SP-A concentrations used in these studies are within the best estimates of the physiological ranges.
The respiratory system continually faces exposure to airborne LPS, PGN, and microbes. SP-A may play an important role in the elimination of these microbes by enhancing phagocytosis by alveolar macrophages. Although SP-A enhances microbial clearance, it also appears to be an important element in dampening the inflammatory response to some organisms and their derivative cell surface components. Alveolar macrophages and neutrophils produce proinflammatory cytokines through the CD14/TLR pathway in response to microbial components including PGN, LPS, and lipoteichoic acid. TNF-␣ is a pivotal mediator of the host responses to infections and triggers inflammatory responses. Because overproduction of TNF-␣ can cause chronic pathological states especially in the lung, the inhibitory function of SP-A on TNF-␣ release may be crucial regulatory component for controlling pulmonary inflammation.
In conclusion, this study demonstrates that SP-A inhibits TNF-␣ secretion induced by PGN. The results also reveal that SP-A directly binds TLR2, alters the interaction of TLR2 with PGN, and attenuates downstream signaling events. These findings provide one mechanistic framework by which SP-A can regulate inflammatory responses in the alveolar compartment.
